Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Tetra Bio-Pharma Inc. (TBP) announces its public offering of units for aggregate gross proceeds of $6.8 million
  • Tetra has granted the agents involved an option to increase the size of the offering by up to an additional number of units
  • It is to cover over-allotments, and for market stabilization purposes
  • The net proceeds from the offering will be used by Tetra for clinical trials, working capital and general corporate purposes
  • Tetra Bio-Pharma Inc. (TBP) is down 12.5 per cent trading at $0.14 per share as of 3:17 p.m. EST

Tetra Bio-Pharma Inc. (TBP) announces its public offering of units for aggregate gross proceeds of $6.8 million.

Each unit will be comprised of one common share of and one common share purchase warrant of Tetra.

Each warrant will entitle the holder thereof to purchase one common share at an exercise price of $0.195 per share.

Tetra has granted the agents involved an option to increase the size of the offering by up to an additional number of units.

It is to cover over-allotments, and for market stabilization purposes, exercisable at any time and from time to time up to 30 days following the closing.

The net proceeds from the offering will be used by Tetra for clinical trials, working capital and general corporate purposes.

The closing of the offering is expected to occur by December 20, 2021.

Tetra intends to file a prospectus supplement to its short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Quebec.

Tetra’s evidence-based scientific approach has enabled the company to develop a pipeline of cannabinoid-based drug products.

It is intended for a range of medical conditions, including pain, inflammation, and oncology.

Tetra is focused on providing scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians, and insurance companies.

Tetra Bio-Pharma Inc. (TBP) is down 12.5 per cent trading at $0.14 per share as of 3:17 p.m. EST.

More From The Market Herald

" Algernon Pharmaceuticals (CSE:AGN) discloses novel salt patent strategy

Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188 (“N,N-dimethyltryptamine” or “DMT”).
Nextech AR - CEO, Evan Gappelberg

" Nextech AR (CSE:NTAR) announces $10M private placement

Nextech AR (NTAR) has announced a private placement with an institutional investor for gross proceeds of approximately $10 million.

" Summa Silver (TSXV:SSVR) upsizes private placement

Summa Silver Corp. (SSVR) has upsized its brokered private placement offering for gross proceeds of up to $10 million.

" LevelJump Healthcare (TSXV:JUMP) announces $2.5M private placement

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.